Tetragenetics to work with MedImmune on antibody research; Genentech partners with 23andMe on Parkinson's project;

@FierceBiotech: Aveo guts its R&D operation, cutting two-thirds of its payroll. Item | Follow @FierceBiotech

@JohnCFierce: Eyeing an IPO, Genkyotex banks a $21M round for PhII study -- NOX inhibition. Story | Follow @JohnCFierce

@DamianFierce: Another roughly $65M in biotech VC announced today, making for a three-day total nearing $700M. | Follow @DamianFierce

> Cambridge, MA-based Tetragenetics will collaborate with MedImmune on antibody drug discovery research. Release

> 23andMe and Genentech plan to generate whole genome sequencing data for about 3,000 people in 23andMe's Parkinson's disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson's disease. Release

Medical Device News

@FierceMedDev: Graphene 'flying carpet' strips deliver two #cancer drugs, each to a different cell target. Article | Follow @FierceMedDev

@EmilyWFierce: Cancer Genetics gets nod to offer cancer testing in California. Story | Follow @EmilyWFierce

> FDA clears pivotal trial for permanent use of artificial heart. Story

> Shockwave's energy-delivering angioplasty balloon for PAD receives CE mark. Article

> New technology can spot cavities early, but is that necessary? News

Pharma News

@FiercePharma: Whistle-blowing Bayer sales rep wins again in wrongful termination suit. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bayer drafts 'Community' star to launch cult-favorite hangover cure in U.S. More | Follow @CarlyHFierce

> New study clears Merck's blockbuster Gardasil of MS risk. News

> Roche and GSK set for sales growth in this year's fast-spreading flu epidemic. Report

Drug Delivery News

> Palo Alto pain management startup Carbylan vies for $86M IPO. Article

> Blend Therapeutics receives $21M in Series B round. Item

> Australia's EnGeneIC receives $10M in Series B round for studies of anticancer delivery tech. News

> Graphene 'flying carpet' strips deliver two cancer drugs, each to a different cell target. Report

> NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial. More

Diagnostics News

> HTG Molecular Diagnostics mulls $60M IPO for next-gen profiling technology. Report

> Illumina blazes into 2015 with plans for new California campus. News

> Molecular Dx maker CombiMatrix wins a battle in insurance fraud lawsuit. Article

> Cancer Genetics gets nod to offer cancer testing in California. More

> Israel's Itamar looks to China, Canada and beyond for growth. Story

Pharma Marketing News

> Do rival DTC campaigns help your own brand? Yes, a study shows--up to a point. Report

> FDA's marketing police wrote only 10 tickets in 2014. Story

> Whistle-blowing Bayer sales rep wins again in wrongful termination suit. More

> Pfizer complains, advertising watchdog acts against Novartis Theraflu promo. Article

> Bayer drafts 'Community' star to launch cult-favorite hangover cure in U.S. News

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.